Form 4: Century Therapeutics SVP Sells Shares for Tax Obligations

SVP of Finance & Operations Douglas Carr sold 264 shares of Century Therapeutics to cover tax withholding obligations related to RSU vesting.

Summary

• Douglas Carr, SVP of Finance & Operations at Century Therapeutics, Inc. (IPSC), sold 264 shares of common stock.
• The transaction occurred on May 4, 2026, at a price of $2.341 per share.
• The sale was executed automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• Following this transaction, Douglas Carr retains beneficial ownership of 506,997 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory for tax purposes rather than a discretionary divestment.

Positives

• The transaction was non-discretionary and mandated by tax withholding requirements, indicating no change in the executive's long-term outlook on the company.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• The company remains subject to market volatility and the inherent risks associated with the biotechnology sector.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this filing.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that automatic sell-to-cover transactions are standard practice for corporate executives in the biotechnology industry to manage tax liabilities arising from equity compensation vesting schedules.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance.
• The volume of shares sold is negligible relative to the total outstanding shares of the company.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Century Therapeutics, IPSC, Insider Trading, Form 4, Biotechnology, Equity Compensation